Impact of pegylated interferon α-2B and ribavirin on hepatic fibrosis in liver transplant patients with recurrent hepatitis C: an open-label series
Article first published online: 2 MAY 2006
Volume 26, Issue 5, pages 529–535, June 2006
How to Cite
Mukherjee, S. and Lyden, E. (2006), Impact of pegylated interferon α-2B and ribavirin on hepatic fibrosis in liver transplant patients with recurrent hepatitis C: an open-label series. Liver International, 26: 529–535. doi: 10.1111/j.1478-3231.2006.01261.x
- Issue published online: 25 MAY 2006
- Article first published online: 2 MAY 2006
- Received 17 October 2005,accepted 20 February 2006
- – pegylated interferon;
- – recurrent hepatitis C;
- – ribavirin
Abstract: Background: Patients with recurrent hepatitis C virus (HCV) are often treated with interferon-based therapy in an attempt to eradicate HCV and prevent cirrhosis requiring retransplantation. We describe our experience with pegylated interferon and ribavirin and the impact of this therapy on hepatic fibrosis.
Methods: Patients were treated with pegylated interferon α-2b 1.5 mcg/kg/week and ribavirin 800 mg/day for 6–12 months according to genotype. HCV ribonucleic acid (HCV RNA) was repeated at 3 months, end of treatment (EOT) and 6 months after EOT for patients HCV RNA negative at EOT. Liver biopsies were performed prior to treatment and at EOT.
Results: Thirty nine patients were eligible. Twenty two completed treatment and 17 (43.6%) were intolerant. Eleven of 22 (50%) patients who completed treatment developed sustained viral response (SVR). Two patients intolerant to treatment also developed SVR. Serial biopsies were performed in 17 patients and refused in five. Improved fibrosis scores were present in four patients (non-responders, n=2), unchanged in 10 (non-responders, n=4), and worse in three (all non-responders).
Conclusions: Side effects are an important limiting factor in recurrent HCV treatment with SVR only 33.3% in an intention-to-treat analysis. However, improved or stable fibrosis scores were also demonstrated in 66.7% of non-responders. This suggests failure to eradicate HCV should not necessarily lead to treatment discontinuation as a subgroup of patients may benefit from maintenance therapy.